BIVN Bioenvision (MM)

Bioenvision Inc. (NasdaqGM:BIVN) will hold a live webcast of its quarterly conference call at 10:00a.m. EST on Thursday, February 8th, 2007. Jim Scibetta, Chief Financial Officer, will host the call. Senior management will discuss the Company�s financial results as of December 31, 2006, the progress towards its goals, and additional corporate activities, including the EMeA filing for Evoltra� in adult acute myeloid leukemia (AML). Bioenvision will announce the highlights of these topics in a press release to be issued before the market opens on February 8, 2007, prior to the conference call. Conference Call Information: Date: 2/8/07 Time: 10:00a.m. Eastern Standard Time Toll free (US & Canada): 866-585-6398 International: 416-849-9626 Webcast: www.bioenvision.com A replay of the call and webcast will be available for 14 days. Replay number (US & Canada): 866-245-6755 Replay number international: 416-915-1035 Replay passcode: 752762 Webcast replay: www.bioenvision.com About Bioenvision Bioenvision's primary focus is the acquisition, development and marketing of compounds and technologies for the treatment of cancer. Bioenvision has a broad pipeline of products for the treatment of cancer, including: Evoltra�, Modrenal� (for which Bioenvision has obtained regulatory approval for marketing in the United Kingdom for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy), and other products. Bioenvision is also developing anti-infective technologies, including the OLIGON� technology; an advanced biomaterial that has been incorporated into various FDA approved medical devices and Suvus�, an antimicrobial agent currently in clinical development for refractory chronic hepatitis C infection. For more information on Bioenvision please visit our Web site at www.bioenvision.com. Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because these statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Specifically, factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to: risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and in Bioenvision's compounds under development in particular; the potential failure of Bioenvision's compounds under development to prove safe and effective for treatment of disease; uncertainties inherent in the early stage of Bioenvision's compounds under development; failure to successfully implement or complete clinical trials; failure to receive marketing clearance from regulatory agencies for our compounds under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Bioenvision's business, structure or projections; the development of competing products; uncertainties related to Bioenvision's dependence on third parties and partners; and those risks described in Bioenvision's filings with the SEC. Bioenvision disclaims any obligation to update these forward-looking statements.